Company Overview
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -5.6%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -5.59% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -28.00% |
| 6 Months: | +10.20% |
| 3 Months: | -24.48% |
| 1 Month: | -23.94% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)23.10 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -5.6% CAGR over 5 years.
- Trading 46.8% below its 52-week high.
- RSI at 23 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NNVC NanoViricides, Inc. PHARMA | 1.08 | -2.45 | $27.57M | 0.00% | -127.59% | -89.97% | - | -5.59% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.25M | 2.12M | 1.80M | 2.23M | 2.03M |
| Operating Income | -1.89M | -1.75M | -1.23M | -1.69M | -1.70M | -1.12M | -2.23M | -2.09M | -2.05M | -2.44M | -2.30M | -2.62M | -2.23M | -2.39M | -2.42M | -2.04M | -2.37M | -2.08M | -1.99M | -1.63M | -2.54M | -2.27M | -2.29M | -2.11M | -2.61M | -1.92M | -1.79M | -1.62M | -1.83M | -1.81M | -2.03M | -2.18M | -1.91M | -3.17M | - | -2.25M | -2.12M | -1.80M | -2.23M | -2.03M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.03M | -1.93M | -1.66M | -2.09M | -1.86M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 149 | 0 | 0 | - | 0 | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.22M | -2.10M | -1.79M | -2.22M | -1.99M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.27M | -1.36M | 1.32M | 851.70K | -1.88M | -251.02K | -1.31M | -2.78M | -4.99M | -3.06M | -1.55M | -3.14M | -2.01M | -2.80M | -2.11M | -1.84M | -2.23M | -2.14M | -1.56M | -1.93M | -8.08M | -2.31M | -2.33M | -2.11M | -2.61M | -1.92M | -1.79M | -1.57M | -1.75M | -1.70M | -1.97M | -2.11M | -1.85M | -3.13M | - | -2.22M | -2.10M | -1.79M | -2.22M | -1.99M |
| Diluted EPS | - | -0.03 | -0.02 | 0.02 | -0.04 | -0.02 | -0.02 | -0.05 | -0.09 | -0.05 | -0.03 | -0.05 | -0.03 | -0.04 | -0.03 | - | - | - | - | - | - | -0.22 | -0.22 | -0.19 | -0.23 | -0.17 | -0.16 | -0.14 | -0.15 | -0.15 | -0.17 | -0.18 | -0.16 | -0.23 | -0.14 | -0.14 | - | -0.10 | -0.11 | -0.09 |
| R&D Expense | 1.17M | 1.13M | 625.74K | 811.11K | 916.74K | 546.46K | 1.28M | 1.15M | 1.07M | 1.45M | 1.26M | 1.56M | 1.45M | 1.64M | 1.29M | 1.41M | 1.66M | 1.31M | 1.48M | 1.01M | 1.13M | 1.57M | 1.49M | 1.46M | 2.10M | 1.26M | 1.26M | 1.11M | 1.17M | 1.20M | 1.47M | 1.57M | 1.21M | 1.93M | 1.16M | 1.28M | - | 993.07K | 1.12M | 1.29M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 8.11M | 8.94M | 8.52M | 9.59M |
| Operating Income | -6.08M | -6.59M | -8.67M | -7.06M | -8.86M | -9.60M | -9.33M | -8.66M | -8.00M | -8.74M | -8.11M | -8.94M | -8.52M | -9.59M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -7.38M | -7.84M | -7.49M | -8.72M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 5.12K | 938 | 49.81K | 149 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -8.11M | -8.59M | -8.29M | -9.47M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - |
| Net Income | -6.21M | -8.88M | -13.60M | -2.20M | -10.72M | -10.30M | -8.56M | -8.42M | -13.45M | -8.82M | -8.11M | -8.59M | -8.29M | -9.47M |
| Diluted EPS | - | -0.19 | -0.27 | -0.09 | -0.19 | -0.17 | -0.13 | - | - | -0.81 | -0.70 | -0.74 | -0.70 | -0.63 |
| R&D Expense | 4.27M | 4.29M | 5.13M | 3.66M | 5.03M | 6.57M | 5.91M | 5.92M | 4.70M | 6.11M | 5.78M | 6.39M | 5.44M | 5.55M |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2005 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Nov 2017 | Mar 2018 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 16.41M | 43.86M | 44.19M | 36.63M | 27.00M | - | - | 18.55M | 13.45M | 23.91M | 30.26M | 23.49M | 16.90M | 12.82M | 8.82M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.42M | 8.45M | 4.97M | 1.67M |
| Cash & Equivalents | - | 9.22M | 14.27M | 13.92M | 36.70M | 31.47M | 24.16M | 15.10M | - | - | 7.08M | 2.56M | 13.71M | 20.52M | 14.07M | 8.15M | 4.80M | 1.56M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | 8.40M | 20.49M | 12.40M | 13.59M | 6.68M | - | - | 881.95K | - | - | - | 412.84K | 2.03M | 1.36M | 1.31M |
| Current Liabilities | - | - | - | 1.18M | 517.74K | 600.89K | 6.74M | 4.67M | - | - | 881.95K | 2.85M | 2.16M | 351.15K | 412.84K | 534.25K | 1.36M | 1.31M |
| Long Term Debt | - | - | - | 0 | 5.00M | 0 | - | - | 4.73M | 4.73M | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 94.79K | - | - | - |
| Total Equity | 0 | 10.17M | 13.85M | 8.01M | 23.37M | 31.79M | 23.05M | 20.32M | - | - | 17.66M | 10.60M | 21.76M | 29.91M | 23.08M | 14.87M | 11.46M | 7.52M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.59M | 11.70M | 13.14M | 16.61M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -6.83M | -7.90M | -7.78M | -6.80M | -6.67M | -8.21M | -5.89M | -5.67M | -6.32M | -8.48M |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - | -324.35K | -151.71K | -156.56K | -56.96K |
| Financing Cash Flow | - | - | - | - | - | -1.00M | 0 | 2.35M | 17.83M | 15.26M | -234.72K | -94.79K | 3.12M | 5.30M |
| Capital Expenditure | -23.35K | -64.93K | -5.23M | -6.76M | -476.37K | -164.98K | -241.82K | -73.79K | -8.64K | -238.76K | -324.35K | -151.71K | -156.56K | -56.96K |
| Free Cash Flow | - | - | - | - | -7.31M | -8.06M | -8.02M | -6.88M | -6.67M | -8.45M | -6.22M | -5.82M | -6.47M | -8.54M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -6.45M | -5.92M | -3.35M | -3.24M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -44.8% | -110.8% | -58.2% | -6.9% | -46.5% | -50.7% | -48.5% | -79.5% | -61.8% | -29.5% | -35.1% | -57.8% | -72.3% | -125.9% |
| ROCE % | - | -43.3% | -20.0% | -16.2% | -29.6% | -43.0% | -52.8% | -81.7% | -36.8% | -29.2% | -35.2% | -54.6% | -74.3% | -127.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.60% | 919.31K | $1.31M |
| 2 | Geode Capital Management, LLC | 0.85% | 216.02K | $306.75K |
| 3 | Connective Capital Management LLC | 0.73% | 185.22K | $263.01K |
| 4 | Blackrock Inc. | 0.62% | 158.75K | $225.43K |
| 5 | Vanguard Fiduciary Trust Co | 0.52% | 131.92K | $187.33K |
| 6 | Renaissance Technologies, LLC | 0.50% | 128.60K | $182.61K |
| 7 | Miller Financial Services LLC | 0.44% | 112.00K | $159.04K |
| 8 | UBS Group AG | 0.39% | 99.33K | $141.05K |
| 9 | Creative Planning | 0.34% | 86.76K | $123.20K |
| 10 | Susquehanna International Group, LLP | 0.24% | 60.62K | $86.07K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NNVC
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
SHELTON, CT / ACCESS Newswire / September 8, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummie…
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
SHELTON, CT / ACCESS Newswire / August 31, 2026 / , Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nan…
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received regulatory approval …
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received National Ethics Committe…
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan
Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical Trial of Monkeypox Treatment to the Democ…
NNVC — Frequently Asked Questions
What is the current share price of NanoViricides, Inc. (NNVC)?
As of 2026-09-19 21:16 PDT, NanoViricides, Inc. (NNVC) trades at $1.08 on NYSE American. Its 52-week range is $0.85 to $2.03.
What is the market capitalisation of NNVC?
NanoViricides, Inc. (NNVC) has a market capitalisation of $27.57M on NYSE American.
What is the P/E ratio of NNVC?
NNVC trades at a trailing price-to-earnings (P/E) ratio of -2.45. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.36.
What is the return on equity (ROE) of NNVC?
NNVC has a return on equity (ROE) of -89.97%. Its return on capital employed (ROCE) is -127.59%.
Is NNVC a good stock to buy?
This page provides a data-driven analysis of NanoViricides, Inc. (NNVC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.